CClinicalTrials.gg
Not yet recruitingNCT07781007Updated Sep 11, 2026

Effectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older Adults With Schizophrenia

An interventional study of Scaffolding-Based Board Game Intervention in Schizophrenia, sponsored by Kaohsiung Kai-Suan Psychiatric Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Kaohsiung Kai-Suan Psychiatric Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of a scaffolding-based board game intervention on cognitive and functional outcomes in older adults with schizophrenia living in psychiatric nursing homes. Participants will be assigned by clusters to either an intervention group or a control group. The intervention group will receive a 12-week board game training program, while the control group will receive usual care. Cognitive and functional outcomes will be assessed before the intervention, immediately after the 12-week intervention, and three months after the intervention. The study will examine whether the board game intervention can improve cognitive and daily functioning in older adults with schizophrenia.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Older Adults
  • Board Game Intervention
  • Cognitive Function
  • Psychiatric Nursing Home
03

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 55 years or older.
  2. Diagnosed with schizophrenia by a board-certified psychiatrist.
  3. Has completed at least elementary school education.
  4. Has basic verbal communication ability and is able to understand and cooperate with study assessments and activities.
  5. Has sufficient vision and hearing, as assessed by care staff, to participate in board game instructions and activities.
  6. Is willing to participate in the study and provides written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Has severe sensory impairment.
  2. Has severe visual or hearing impairment that interferes with participation in the study activities.
  3. Has experienced an acute exacerbation of psychiatric symptoms within the past 3 months.
  4. Is currently receiving other cognitive training or participating in another research study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Scaffolding-Based Board Game Intervention

    Behavioral: Scaffolding-Based Board Game Intervention

  • No intervention
    Control Group

Interventions

  • BehavioralScaffolding-Based Board Game Intervention

    Participants will receive a scaffolding-based board game intervention once weekly for 12 weeks, with each session lasting approximately 60 minutes.

05

What researchers measure

Primary outcomes

  1. Cognitive Function Assessed by MoCA-TW 7.1

    The Montreal Cognitive Assessment-Taiwan Version 7.1 (MoCA-TW 7.1) is used to assess global cognitive function. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline, immediately after the 12-week intervention, and 3 months after completion of the intervention

06

Study locations

1 site
  • Daliao Psychiatric Nursing Home, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
    Kaohsiung City, Taiwan
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07781007
Lead sponsor
Kaohsiung Kai-Suan Psychiatric Hospital
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Sep 9, 2026 (estimated)
Primary completion
Dec 2, 2026 (estimated)
Completion
Mar 2, 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

CHIU JUNG CHANG
Contact
joce0989@gmail.com
+886-989-341-120

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion